» Articles » PMID: 24337102

Infusion of Pharmaceutical-grade Natural Human C-reactive Protein is Not Proinflammatory in Healthy Adult Human Volunteers

Overview
Journal Circ Res
Date 2013 Dec 17
PMID 24337102
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Baseline circulating concentrations of C-reactive protein (CRP) are significantly associated with cardiovascular disease risk in general populations. This modest association has been inappropriately conflated with causality, and it has been claimed that CRP is proatherogenic. Most of the known causative factors for atherosclerosis stimulate increased CRP production, but comprehensive genetic epidemiology studies provide no support for a pathogenic role of CRP. The reported proinflammatory effects of human CRP preparations on healthy cells in vitro and in healthy animals in vivo have all been produced by poorly characterized CRP preparations, demonstrably caused by impurities, or elicited by CRP made in recombinant Escherichia coli not by humans. None of the in vitro or animal findings have been reproduced with pure natural human CRP. Nevertheless, the strong proinflammatory effects of infusing recombinant bacterial CRP into humans have still been inappropriately ascribed to CRP.

Objective: To investigate the effects of infusion into healthy adult human volunteers of pure natural human CRP.

Methods And Results: Comprehensively characterized, pharmaceutical-grade, endotoxin-free, purified CRP, prepared to GMP standard from pooled normal human donor plasma was infused as an intravenous bolus in 7 healthy adult human volunteers at ≤2 mg/kg to provide circulating CRP concentrations ≤44 mg/L. No recipient showed any significant clinical, hematologic, coagulation, or biochemical changes, or any increase in proinflammatory cytokines or acute phase proteins.

Conclusions: The human CRP molecule itself is not proinflammatory in healthy human adults.

Citing Articles

IL-6 and Cardiovascular Risk: A Narrative Review.

Mehta N, deGoma E, Shapiro M Curr Atheroscler Rep. 2024; 27(1):12.

PMID: 39589436 PMC: 11599326. DOI: 10.1007/s11883-024-01259-7.


C-Reactive Protein in Atherosclerosis-More than a Biomarker, but not Just a Culprit.

Kirkgoz K Rev Cardiovasc Med. 2024; 24(10):297.

PMID: 39077585 PMC: 11262456. DOI: 10.31083/j.rcm2410297.


Being Eaten Alive: How Energy-Deprived Cells Are Disposed of, Mediated by C-Reactive Protein-Including a Treatment Option.

Sheriff A, Kunze R, Brunner P, Vogt B Biomedicines. 2023; 11(8).

PMID: 37626775 PMC: 10452736. DOI: 10.3390/biomedicines11082279.


C-reactive protein: a target for therapy to reduce inflammation.

Rizo-Tellez S, Sekheri M, Filep J Front Immunol. 2023; 14:1237729.

PMID: 37564640 PMC: 10410079. DOI: 10.3389/fimmu.2023.1237729.


Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis.

Wagner F, Mansfield J, Lekkerkerker A, Wang Y, Keir M, Dash A Gut. 2023; 72(8):1451-1461.

PMID: 36732049 PMC: 10359578. DOI: 10.1136/gutjnl-2022-328387.